IL13RA2 (Interleukin 13 Receptor Subunit Alpha 2)

In this review, we compare the designs and findings of these three studies and synthesize key lessons. We also outline future perspectives to improve the efficacy of CAR-T cell therapy in solid tumors, with a focus on glioblastoma.

Therefore, in the differential diagnosis between SCT and LCT, our results suggest LEF1 is a highly sensitive and specific immunohistochemical marker and may represent a robust alternative to β-catenin, offering clearer nuclear staining and easier interpretation. The detection of IL13Rα2 in a subset of LCTs is a novel finding and suggests potential biological and therapeutic relevance, warranting further investigation in larger and clinically aggressive cohorts.

NXP900 also synergized with gemcitabine/cisplatin chemotherapy, enhancing antitumor efficacy in both in vitro and in vivo models. IL13RA-AKT signaling was upregulated in resistant models; NXP900 sensitivity could be restored with AKT or IL13RA2 inhibition. Together, these findings demonstrate the therapeutic potential of NXP900 as a novel YAP inhibitor in CCA and support further investigation in a clinical trial.

We develop mathematical models to analyze IL-13R$alpha$2-targeting CAR-T cells and the oncolytic virus C134 using patient-derived glioblastoma data...Models with and without CAR-T exhaustion produce identical fits, indicating that exhaustion dynamics do not improve predictions within the 72-hour observation window. Overall, our results demonstrate that simplified QSS formulations effectively capture viral dynamics and provide a practical framework for optimizing combination immunotherapies.

A2b11-liposomes loaded with sodium fluorescein (FLA) and A2b11-liposomes loaded with temozolomide (TLA) were evaluated for their anti-GBM effects...The A2b11 peptide-modified liposomal system developed in this study represents a promising platform for GBM-targeted therapy. Further research and development of this platform could lay the groundwork for its future clinical application.

Therapeutic cargo consists of epirubicin and the temozolomide metabolite 5-aminoimidazole-4-carboxamide...Despite a lower drug-loading capacity than single-peptide formulations, it induced greater glioma cell death, underscoring the enhanced therapeutic synergy of its dual-peptide, dual-drug design. Fluorescence studies confirm superior uptake and nuclear delivery, establishing C-dots as a stable, cost-effective, modular platform for next-generation personalized cancer nanotherapies.

Additionally, we further demonstrated the efficacy of CAR T cells against patient-derived GBM cells within the GOC model. Collectively, these findings highlight the GOC platform as a powerful preclinical screening tool for cancer immunotherapy optimization.

IL13RA2, but not TREM-1, was associated with TNFA response. In CD, its prediction accuracy improves when combined with OSM.

P1, N=30, Suspended, Yang Zhang | Recruiting --> Suspended

Combined RT and intratumoral administration of GB13 decreased tumor burden and prolonged survival in orthotopic xenograft and genetically engineered mouse models. These findings indicate that RT plus GB13 is well tolerated and effective, informing future investigation of a novel therapeutic approach for DIPG.

The immune microenvironments of CR-SRCC and G-SRCC are distinct from non-SRCC. Broadly, both CR-SRCC and G-SRCC are characterized by a complex immune microenvironment that features cytotoxic cells and innate immune activity that may facilitate immune evasion.

PCA analysis was also conducted to determine the most prominent components that contribute to the dynamic motion of the complexes and the unbound receptor using Schrodinger. Molecular docking studies were carried out using Autodock Vina 1.1.2 as well as DockThor and HPEPDOCK webservers.